Effecty Review
Best for: nationwide compounded semaglutide with brand-name fallback
Effecty offers compounded GLP-1 injections ($160–$205/mo) plus brand-name Ozempic, Wegovy, Zepbound, and Mounjaro. LegitScript certified. Ships to all states nationwide. No membership fees.
High confidence · Last verified 2026-04-10 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Effecty is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| GLP-1 Injection (12-mo plan) | compounded | $160 |
| GLP-1 Injection (1-mo) | compounded | $205 |
| Ozempic | brand | $1300 |
| Wegovy | brand | $1600 |
| Zepbound | brand | $1400 |
| Mounjaro | brand | $1300 |
✓ Pros
- •Both compounded and brand-name GLP-1 options (Ozempic, Wegovy, Zepbound, Mounjaro)
- •LegitScript certified
- •Ships to all states nationwide
- •No membership fees — transparent pricing
- •Compounded semaglutide from $160/mo on annual plan
✗ Cons
- •Compounded option is semaglutide only — no compounded tirzepatide
- •Brand-name options at full retail price ($1,300–$1,600/mo)
- •Also offers longevity and women's HRT (broader platform)
Ready to start with Effecty?
Starting at $160/month. See current pricing and start your free consultation.
Sources & methodology
Our Effecty review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Effecty
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with Effecty?
Starting at $160/month. See current pricing and start your free consultation.